Charles Sinclair

Charles Sinclair joined Flagship Pioneering in 2022. He is head of the Translational Sciences function, accountable for translational research and biomarker strategy in support of the Pioneering Medicines portfolio.

Charles has experience spanning multiple therapeutic areas and modalities. Prior to Flagship, he was a Senior Principal Scientist at Bristol Myers Squibb (BMS), where he served as a program lead for multiple discovery stage small molecule programs that targeted mechanisms of tumor-intrinsic cancer resistance. Prior to BMS, he was an immuno-oncology Team Leader within the bioscience group at AstraZeneca (Cambridge, UK) and was the biology lead of a FOXP3-targeted antisense oligonucleotide program that is currently in Ph1a/b clinical trials.

Before joining the biotech industry, Charles was a postdoctoral researcher and Marie Curie CASCADE fellow at Emory University studying immuno-metabolic crosstalk during inflammatory diseases and vaccination. He had previously completed a Ph.D. and short postdoc at the MRC National Institute for Medical Research (London, UK) studying T-cell homeostasis and development.

Charles has published papers and review articles in areas of immunology, immuno-oncology and cancer, including first/corresponding author publications in Science, Proceedings of the National Academy of Sciences, and Oncoimmunology. Charles received a B.Sc. degree (first class hons) from the University of Warwick (Warwick, UK), and a Ph.D. from the MRC National Institute for Medical Research (London, UK).